Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | PDE9A | O76083 | 2/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20315026 | 0.88 | RPS6KA3 (0.38) | RPS6KA3OPRL1GSK3BMAPTCHRNB2 | |
| SCHEMBL21973762 | 0.83 | CYP11B2 (0.43) | RPS6KA3OPRL1GSK3BMAPTCHRNB2 | |
| SCHEMBL31250373 | 0.77 | RPS6KA3 (0.36) | RPS6KA3GSK3BMAPTCHRNB2CHRNA4 | |
| SCHEMBL25299644 | 0.77 | RPS6KA3 (0.36) | RPS6KA3GSK3BMAPTCHRNB2CHRNA4 | |
| SCHEMBL22156257 | 0.76 | ADRA2A (0.39) | OPRL1PDE10ACYP3A4 | |
| SCHEMBL25147505 | 0.75 | RPS6KA3 (0.47) | RPS6KA3OPRL1DYRK1AGSK3BCHRNB2 | |
| SCHEMBL20314858 | 0.74 | IDO1 (0.39) | RPS6KA3OPRL1CHRNB2CHRNA4 | |
| SCHEMBL29939336 | 0.71 | RPS6KA3 (0.50) | RPS6KA3OPRL1DYRK1AGSK3BMAPT | |
| SCHEMBL12030298 | 0.71 | RPS6KA3 (0.61) | RPS6KA3OPRL1DYRK1AGSK3BAOC3 | |
| SCHEMBL16702989 | 0.71 | RPS6KA3 (0.50) | RPS6KA3OPRL1DYRK1AGSK3BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780821-B2 | Inhibitors of fibroblast activation protein | Praxis Biotech LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230117631-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117631-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | RPS6KA3 253/4885OPRL1 2329/4885DYRK1A 860/4885 |
| US-11780821-B2 | Inhibitors of fibroblast activation protein | FAP, FIBP, FRS2 | RPS6KA3 1494/4885OPRL1 4821/4885DYRK1A 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.